Drug Approval | February 26, 2025
Amgen India investment totals $200 million through 2025
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
Ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis
Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Subscribe To Our Newsletter & Stay Updated
_256_384.JPG)
